Skip to main content
. 2020 Jun 19;83(4):1150–1159. doi: 10.1016/j.jaad.2020.06.051

Table II.

Summary of large case series and registry data of autoimmune disease patients infected or exposed to SARS-CoV-2

Characteristics Studies
Haberman et al71 Gianfrancesco et al72 Brenner et al73
Total number of patients 86 110 525
Confirmed cases of COVID-19 59 (69) 110 (100) 525 (100)
Age, mean y 46 N/A 43
Female sex 49 (57) 79 (72) 243 (46.3)
Most common diagnosis PsA: 21 (24) RA: 40 (36) CD: 312 (59.4)
Other diagnoses RA: 20 (23) PsA: 19 (17) UC: 203 (38.7)
CD: 20 (23) SLE: 19 (17) IBD unspecified: 7 (1.3)
UC: 17 (20) Other: 17 (15)§
Psoriasis: 14 (16) AS: 7 (6)
AS: 9 (10) Vasculitis: 7 (6)
SjS: 5 (5)
Medications
Biologic drugs TNFi: 38 (44) Unspecified: 49 (45) TNFi alone: 176 (33.5)
IL-17i: 6 (7) IL-12/23i: 55 (10.5)
IL-12/23i: 6 (7) TNFi + DMARD: 52 (9.9)
IL-23i: 3 (3) α-Integrin: 50 (9.5)
JAKi 6 (7) 5 (5) 8 (1.5)
csDMARD MTX: 17 (20) 69 (63) 110 (21)
Hydroxychloroquine 8 (9) N/A 0
Hospitalization 14 (16) 39 (35) 161 (31)
Deaths 1 (1) 6 (5) 16 (3)

AS, Ankylosing spondylitis; CD, Crohn's disease; COVID-19, coronavirus disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; IL, interleukin; JAK, Janus kinase inhibitor; MTX, methotrexate; N/A, not available; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2; SjS, Sjögren syndrome; SLE, systemic lupus erythematosus; TNFi, tumor necrosis factor-α inhibitor; UC, ulcerative colitis.

Data are shown as number (%) or as indicated otherwise.

Includes both confirmed and highly suspected cases of COVID-19.

20% of patients were aged >65 years.

§

Other included (all with n < 5): inflammatory myopathy, ocular inflammation, other inflammatory arthritis, polymyalgia rheumatica, sarcoidosis, systemic sclerosis, osteoporosis, psoriasis, isolated pulmonary capillaritis, gout, and autoinflammatory disease.